{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:57:23Z","timestamp":1786993043289,"version":"build-2736575974"},"reference-count":17,"publisher":"Stanford University Press","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jmsacl.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T12:38:20Z","timestamp":1719319100000},"page":"14-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Despite the improved clinical sensitivity of the Roche benzodiazepines II assay it cannot replace mass spectrometry in all patient populations"],"prefix":"10.21627","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-1843","authenticated-orcid":false,"given":"Nicole V.","family":"Tolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Uljon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lauren Donnelly-Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Mahowald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion L.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8549-5299","authenticated-orcid":false,"given":"Lindsey","family":"Contella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3475-6135","authenticated-orcid":false,"given":"Elizabeth D.","family":"Urwiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Daluz Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4209-6085","authenticated-orcid":false,"given":"Stacy E.F.","family":"Melanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4811","reference":[{"key":"10.1016\/j.jmsacl.2024.06.002_b0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.cca.2012.03.017","article-title":"Therapeutic monitoring of benzodiazepines in the management of pain: Current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety","volume":"413","author":"Mikel","year":"2012","journal-title":"Clinica Chimica Acta."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0010","series-title":"Clinical Toxicology Testing - A Guide for Laboratory Professionals","first-page":"132","article-title":"Benzodiazepines","author":"Snyder","year":"2012"},{"key":"10.1016\/j.jmsacl.2024.06.002_b0015","unstructured":"Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network (DAWN): Findings from Drug-Related Emergency Department Visits, 2022. 2022 [cited 2024 Apr 11]; Available from: https:\/\/www.samhsa.gov\/data\/."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: A review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol. Depend."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0025","doi-asserted-by":"crossref","unstructured":"V.R. Votaw, R. Geyer, M.M. Rieselbach, R.K. McHugh. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. Elsevier Ireland Ltd; 2019. p. 95\u2013114.","DOI":"10.1016\/j.drugalcdep.2019.02.033"},{"key":"10.1016\/j.jmsacl.2024.06.002_b0030","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.15816","article-title":"Benzodiazepine Misuse: An Epidemic Within a Pandemic","author":"Sarangi","year":"2021","journal-title":"Cureus [Internet]."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0035","unstructured":"Federal Register\u00a0:: Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I [Internet]. [cited 2024 Apr 11]. Available from: https:\/\/www.federalregister.gov\/documents\/2023\/07\/26\/2023-15748\/schedules-of-controlled-substances-temporary-placement-of-etizolam-flualprazolam-clonazolam."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0040","unstructured":"NPS Benzodiazepines [Internet]. [cited 2024 Apr 11]. Available from: https:\/\/www.cfsre.org\/nps-discovery\/trend-reports\/nps-benzodiazepines."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0045","doi-asserted-by":"crossref","unstructured":"L. Manchikanti, Y. Malla, B.W. Wargo, B. Fellows. Comparative Evaluation of the Accuracy of Benzodiazepine Testing in Chronic Pain Patients Utilizing Immunoassay with Liquid Chromatography Tandem Mass Spectrometry (LC\/ MS\/MS) of Urine Drug Testing. Pain Physician [Internet]. 2011;14:259\u201370.","DOI":"10.36076\/ppj.2011\/14\/259"},{"key":"10.1016\/j.jmsacl.2024.06.002_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1258\/acb.2009.009172","article-title":"Measurement of benzodiazepines in urine by liquid chromatography-tandem mass spectrometry: Confirmation of samples screened by immunoassay","volume":"47","author":"Glover","year":"2010","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0055","first-page":"543","article-title":"Benzodiazepine analysis by an improved LC-MS\/MS method illustrates usage patterns in Washington State","author":"Keung Chan","year":"2023","journal-title":"Clinica Chimica Acta."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0060","first-page":"359","article-title":"KIMS, CEDIA, and HS-CEDIA Immunoassays Are Inadequately Sensitive for Detection of Benzodiazepines in Urine from Patients Treated for Chronic Pain","volume":"17","author":"Darragh","year":"2014","journal-title":"Pain Physician [Internet]."},{"key":"10.1016\/j.jmsacl.2024.06.002_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jmsacl.2023.02.010","article-title":"Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens","volume":"28","author":"Lund","year":"2023","journal-title":"Journal of Mass Spectrometry and Advances in the Clinical Lab"},{"key":"10.1016\/j.jmsacl.2024.06.002_b0070","first-page":"27","article-title":"Comparison of two immunoassay screening methods and a lc\u2010ms\/ms in detecting traditional and designer benzodiazepines in urine","author":"Rossi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jmsacl.2024.06.002_b0075","doi-asserted-by":"crossref","unstructured":"R.B. Dixon, D. Floyd, A. Dasgupta. Limitations of EMIT Benzodiazepine Immunoassay for Monitoring Compliance of Patients With Benzodiazepine Therapy Even After Hydrolyzing Glucuronide Metabolites in Urine to Increase Cross-Reactivity: Comparison of Immunoassay Results With LC-MS\/MS Values. 2014.","DOI":"10.1097\/FTD.0000000000000117"},{"key":"10.1016\/j.jmsacl.2024.06.002_b0080","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1373\/jalm.2018.027342","article-title":"A Rapid Dilute-and-Shoot UPLC-MS\/MS Assay to Simultaneously Measure 37 Drugs and Related Metabolites in Human Urine for Use in Clinical Pain Management","volume":"3","author":"Dahlin","year":"2019","journal-title":"Journal of Applied Laboratory Medicine"},{"key":"10.1016\/j.jmsacl.2024.06.002_b0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/jat\/bkab108","article-title":"Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS","volume":"46","author":"Puzyrenko","year":"2022","journal-title":"J Anal Toxicol."}],"container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X24000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X24000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:22:40Z","timestamp":1767770560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667145X24000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":17,"alternative-id":["S2667145X24000233"],"URL":"https:\/\/doi.org\/10.1016\/j.jmsacl.2024.06.002","relation":{},"ISSN":["2667-145X"],"issn-type":[{"value":"2667-145X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Despite the improved clinical sensitivity of the Roche benzodiazepines II assay it cannot replace mass spectrometry in all patient populations","name":"articletitle","label":"Article Title"},{"value":"Journal of Mass Spectrometry and Advances in the Clinical Lab","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmsacl.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 THE AUTHORS. Publishing services by ELSEVIER B.V. on behalf of MSACL.","name":"copyright","label":"Copyright"}]}}